Applied BioMath, LLC, the industry leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced a collaboration with OncoMyx Therapeutics, a privately-held oncolytic immunotherapy company. Applied BioMath will develop a systems pharmacology model to mechanistically evaluate the pharmacokinetics and pharmacodynamics (PK/PD) of OncoMyx's oncolytic myxoma virus (MYXV) platform and therapeutic programs. OncoMyx is developing oncolytic immunotherapies based on the MYXV platform to orchestrate an immune response and treat various cancers.
"In previous roles, I have collaborated with Applied BioMath and believe that their systems pharmacology modeling provides significant value to therapeutic development," said Leslie Sharp, Ph.D., Chief Scientific Officer at OncoMyx. "Incorporating this data into our development activities could help de-risk and accelerate our therapeutic programs in oncolytic immunotherapies for a wide range of cancers."
Applied BioMath employs a rigorous fit-for-purpose model development process which aims to quantitatively integrate knowledge about therapeutics with an understanding of its mechanism of action in the context of human disease mechanisms. Their approach provides objective insight to support decision-making throughout discovery, development, and into the clinic enabling project teams to utilize experiments and resources more efficiently.
"Two key components of our modeling approach are the focus on mechanism and fit-for-purpose modeling," said John Burke, PhD, Co-founder, President, and CEO of Applied BioMath. "Incorporating the mechanism allows the model to more accurately reflect the biology of the drug-disease system and translate well across species, while the fit-for-purpose aspect enables us to create and analyze the model in a timely manner so teams have the results for consideration in their decisions."
For more information on examples of how Applied BioMath's modeling approach has helped de-risk and accelerate over 100 projects, please visit www.appliedbiomath.com/case-studies.
About Applied BioMath
Founded in 2013, Applied BioMath's mission is to revolutionize drug invention. Applied BioMath uses mathematical modeling and simulation to provide quantitative and predictive guidance to biotechnology and pharmaceutical companies to help accelerate and de-risk drug research and development. Their approach employs proprietary algorithms and software to support groups worldwide in decision-making from early research through clinical trials. The Applied BioMath team leverages their decades of expertise in biology, mathematical modeling and analysis, high-performance computing, and industry experience to help groups better understand their candidate, its best-in-class parameters, competitive advantages, patients, and the best path forward into and in the clinic. For more information about Applied BioMath and its services, visit www.appliedbiomath.com.
Applied BioMath and the Applied BioMath logo are registered trademarks of Applied BioMath, LLC.
Media contact: Kristen Zannella, firstname.lastname@example.org